Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 3/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526000 | 0.89 | NR1H3 (0.40) | NR1H3ADRB3MAOBMAOAACHE | |
| SCHEMBL7248052 | 0.89 | NR1H3 (0.40) | NR1H3ADRB3MAOBMAOAACHE | |
| SCHEMBL7244459 | 0.89 | NR1H3 (0.40) | NR1H3ADRB3MAOBMAOAACHE | |
| SCHEMBL5194303 | 0.88 | NR1H3 (0.38) | NR1H3ADRB3MAOBMAOAACHE | |
| SCHEMBL1120784 | 0.88 | NPSR1 (0.39) | NR1H3MAOBMAOAACHEALK | |
| SCHEMBL1120896 | 0.78 | GAA (0.42) | NR1H3MAOBMAOAACHEMEN1 | |
| SCHEMBL7250840 | 0.76 | ATM (0.40) | NR1H3MAOBACHEMEN1KMT2A | |
| SCHEMBL7244999 | 0.76 | GRM2 (0.47) | MEN1KMT2AGRM2LMNAPOLB | |
| SCHEMBL2239649 | 0.75 | GRM2 (0.35) | NR1H3MAOBGRM2KCNH2 | |
| SCHEMBL2239656 | 0.75 | GRM2 (0.35) | NR1H3MAOBGRM2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277736-B1 | NOVEL BICYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-7049445-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-05-23 | — | — | US | disclosed |
| US-6861444-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | ASAHI KASEI PHARMA CORPORATION (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1277736-A1 | NOVEL BICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | GPR119, ADRB3, DBH | NR1H3 12/4885ADRB3 2/4885MAOB 489/4885 |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | GPR119, GIPR, SLC5A2 | NR1H3 315/4885ADRB3 953/4885MAOB 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.